Sex hormones and the risk of incident prostate cancer.
OBJECTIVE
To assess whether sex hormone levels are associated with subsequent development of prostate cancer.


METHODS
A case-cohort study was conducted within the ongoing Osteoporotic Fractures in Men cohort study of community-dwelling men ≥ 65 years old recruited at 6 US clinical sites. After a mean follow-up of 4.7 years, all men with incident-confirmed prostate cancer and a random sample of the full cohort (subcohort) were selected for analysis: after excluding men with a history of prostate cancer and those who reported androgen or antiandrogen therapy at baseline, the resulting analytic sample comprised 275 cases and 1652 noncases with complete sex hormone measurements. Serum testosterone, estradiol, estrone, and sex hormone-binding globulin were assayed at baseline (prediagnosis) by gas chromatography combined with mass spectrometry. Associations between incident prostate cancer and each sex hormone were evaluated using Cox proportional hazards regression models adjusted for age, race, study site, body mass index, and person-time.


RESULTS
In the subcohort, the mean age was 73 years. Higher serum estrone was strongly related to an increased risk of prostate cancer: compared with men in the lower quartile, the risk of prostate cancer among those in the highest 3 quartiles (> 24.9 pg/dL) was nearly 4-fold higher (adjusted heart rate = 3.93, CI: 1.61-9.57). Other sex hormones were not associated with the risk of prostate cancer.


CONCLUSIONS
In this cohort of older men, higher estrone levels were strongly associated with an increased risk of incident prostate cancer. This association between estrone and prostate cancer risk needs to be clarified by further study.
Daniels
Nicholas A
NA
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA. ndaniels@medicine.ucsf.edu
Nielson
Carrie M
CM
Hoffman
Andrew R
AR
Bauer
Douglas C
DC
D000368:Aged; D016022:Case-Control Studies; D015331:Cohort Studies; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D008401:Gas Chromatography-Mass Spectrometry; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood*; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood
D012739:Gonadal Steroid Hormones; D012738:Sex Hormone-Binding Globulin; D004970:Estrone; D013739:Testosterone; D004958:Estradiol
Br J Cancer. 2000 Feb;82(3):718-25
10682688
Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1004-8
17507629
J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):158-67
18337090
Comput Methods Programs Biomed. 1997 Nov;54(3):201-8
9421665
J Steroid Biochem. 1982 Jun;16(6):801-10
7202083
J Natl Cancer Inst. 2008 Feb 6;100(3):170-83
18230794
Am J Surg Pathol. 2004 Jul;28(7):928-34
15223964
Contemp Clin Trials. 2005 Oct;26(5):557-68
16085466
J Clin Oncol. 2000 Feb;18(4):847-53
10673527
J Clin Epidemiol. 1999 Dec;52(12):1165-72
10580779
Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1069-74
9865423
J Clin Epidemiol. 1993 Feb;46(2):153-62
8437031
Rev Urol. 2002;4 Suppl 5:S3-S10
16986064
Br J Cancer. 1999 Jun;80(7):930-4
10362098
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98
11836290
J Gerontol A Biol Sci Med Sci. 2005 Mar;60(3):385-90
15860479
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
1279218
Endocr Rev. 2005 Apr;26(2):171-202
15561802
Urology. 2001 May;57(5):930-5
11337297
Contemp Clin Trials. 2005 Oct;26(5):569-85
16084776
Prostate. 2006 Jun 15;66(9):1005-12
16541422
J Natl Cancer Inst Monogr. 2000;(27):39-66
10963619
J Steroid Biochem Mol Biol. 2004 Nov;92(4):297-305
15663993
Int J Cancer. 2004 Jan 20;108(3):418-24
14648709
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2257-60
16172240
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
10523012
Am J Epidemiol. 2001 Jun 15;153(12):1152-8
11415949
J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26
8757191